Donepezil for negative signs in elderly patients with schizophrenia: An add-on, double-blind, crossover, placebo-controlled study

Keyphrases

• Agitation 20%
• Alzheimer's Disease Assessment Scale-Cognitive Subscale 40%
• Cholinergic Neurotransmission 20%
• Cholinesterase 20%
• Chronic Schizophrenia 40%
• Clinical Global Impression Scale 40%
• Cognitive Impairment 40%
• Cognitive Intervention 20%
• Cognitive Status 20%
• Cross Effect 20%
• Dementia 20%
• Diagnostic Criteria 20%
• Disease Duration 20%
• Donepezil 100%
• Donepezil Treatment 20%
• Elderly Patients 100%
• First Week 20%
• Intervention Effect 20%
• Negative Sign 100%
• Negative Symptoms 40%
• Patients with Schizophrenia 100%
• Placebo 20%
• Placebo Treatment 20%
• Placebo-controlled Study 100%
• Positive Symptoms 40%
• Severe Cognitive Impairment 20%
• Status Effect 20%
• Symptom Scale 40%
• Symptom Severity 20%
• Treatment Duration 20%
• Treatment Effect 20%
• Treatment Group 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Alzheimer's Disease 33%
• Cholinergic Receptor Stimulating Agent 16%
• Cholinesterase 16%
• Cognitive Defect 50%
• Disease 16%
• Donepezil 100%
• Negative Syndrome 33%
• Placebo 33%
• Placebo-Controlled Study 100%
• Positive Syndrome 33%
• Schizophrenia 33%
• Symptom 16%

Neuroscience

• Alzheimer's Disease 33%
• Cholinergic Transmission 16%
• Cholinesterase 16%
• Cognitive Disorders 50%
• Dementia Praecox 100%
• Donepezil 100%
• Negative Syndrome 33%
• Placebo 100%
• Positive Syndrome 33%